Sareum Holdings (AIM: SAR)

Last close As at 02/07/2024

GBP0.45

0.50 (1.12%)

Market capitalisation

GBP43m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Latest Insights

View More

Healthcare | Flash note

Sareum Holdings — SDC-1801 records positive Phase Ia data

Healthcare | Update

Sareum Holdings — A decisive period ahead for SDC-1801

Healthcare | Flash note

Sareum Holdings — Positive clinical step forward in SDC-1801

Healthcare | Flash note

Sareum Holdings — SRA737 – new partnership to kick off the year

Sareum Holdings_resized

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

Balance Sheet

Forecast net cash (£m)

0.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 11.4 169.0 (70.6)
Relative 12.9 159.6 (73.4)
52 week high/low 125.0p/10.2p

Financials

Sareum Holdings has announced positive top-line data from the Phase Ia clinical trial for SDC-1801, its lead asset, a novel TYK2/JAK1 inhibitor targeting autoimmune conditions. The results, which include data from the multiple ascending dose (MAD) arm, reiterate the drug-supportive safety profile and once-daily dosing potential, complementing the preliminary data released in February 2024. Notably, no significant change in serum creatinine levels (which tends to affect kidney function) was observed in SDC-1801 treatment, a potential limitation of the TYK2/JAK1 inhibitor category leader, brepocitinib, as seen in several clinical trials. Full, unblinded data from the Phase I study will be available in Q324 and will potentially be followed by a Phase IIa study in psoriasis patients.

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free